G1 Therapeutics Inc at UBS Global Healthcare Conference Transcript
Good afternoon and thank you for coming to the 2019 UBS Global Healthcare Conference. My name is [Brandon], and I'm happy to be your host for this session. Our next presenter is Mark Velleca, CEO of G1 Therapeutics. Following this session, there will be a breakout session in the [Euris] Room. Thank you.
Thank you, [Brandon]. Appreciate the opportunity to share the G1 Therapeutic story with all of you here today in New York City. Also would like to welcome those joining via webcast. G1 is at an important inflection point. We're preparing marketing applications for our first investigational therapy, trilaciclib, and anticipate significant milestones later this year for our next 2 therapies, lerociclib and G1T48.
To remind you, I'll be making forward looking statements today. Our 3 therapeutic candidates address the most common forms of cancer, and our vision is to improve the lives of people affected by these tumors. We've proven our ability to operate in a capital
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
